Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SPY072 · 1 trial · 1 indication
HiSCR75 is defined as at least a 75% reduction from baseline in total abscess and inflammatory nodule count, with no increase in abscess count and no increase in draining tunnel count
| Arm | Type | Description |
|---|---|---|
| SPY072 + bimekizumab | EXPERIMENTAL | Participants receive SPY072 + bimekizumab |
| Placebo + bimekizumab | PLACEBO_COMPARATOR | Participants receive matching placebo for SPY072 + bimekizumab |
| Name | Type | Description |
|---|---|---|
| SPY072 | DRUG | Solution for SC injection |
| Placebo | DRUG | Matching placebo for SC injection |
| bimekizumab | DRUG | Advanced standard of care |
Inclusion Criteria: * Clinical diagnosis of Hidradenitis Suppurativa with symptoms for at least 6 months before screening. * Hidradenitis suppurativa lesions in at least 2 distinct anatomical areas, with at least 1 area meeting Hurley Stage II or III criteria at screening and Day 1. * Total abscess...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 5 | PHASE3 | Upadacitinib |
| Incyte Corporation | INCY | 6 | PHASE3 | Povorcitinib |
| Novartis AG Sponsored ADR | NVS | 11 | PHASE3 | Remibrutinib Dose A, Remibrutinib Dose B |
| MoonLake Immunotherapeutics Class A | MLTX | 2 | PHASE3 | Sonelokimab |
| Sanofi SA Sponsored ADR | SNY | 2 | PHASE2 | Brivekimig |
| Pfizer Inc. | PFE | 1 | PHASE2 | Ritlecitinib |
| Merck & Co., Inc. | MRK | 1 | PHASE2 | Tulisokibart |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | PHASE2 | Zasocitinib |
| Zura Bio Limited Class A | ZURA | 1 | PHASE2 | Tibulizumab Dose A, Tibulizumab Dose B |
| Sonoma Pharmaceuticals, Inc. | SNOA | 2 | PHASE1 | SBT777101 |
| Evommune, Inc. | EVMN | 1 | EARLY_PHASE1 | EVO101 |
SPY072 is an investigational small molecule being developed for the treatment of moderate to severe hidradenitis suppurativa (HS), a chronic inflammatory skin condition. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
The specific molecular target of SPY072 has not been disclosed in the available information. It is described as a small molecule, but its mechanism of action in treating hidradenitis suppurativa is not specified.
SPY072 is being developed by Spyre Therapeutics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol SYRE. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with hidradenitis suppurativa.
SPY072 is currently in Phase 2 clinical development. It is being studied in a randomized, double-blind, placebo-controlled trial for the treatment of moderate to severe hidradenitis suppurativa. The drug is investigational and has not yet received regulatory approval.
SPY072 is being evaluated in a Phase 2 clinical trial with the identifier NCT07766005, known as the SKYLIGHT trial. This study is planned to enroll approximately 150 adult participants with moderate to severe hidradenitis suppurativa in the United States. The trial is not yet recruiting participants.